TABLE 5.

Scenario analyses (FF/UMEC/VI versus BUD/FOR), intent to treat population

	Base case	Scenario	FF/UMEC/VI ICER (cost per QALY gained)
Base case			£1098
Discount rate (costs, benefits)	3.5%	0.0%	£1547
Discount rate (costs, benefits)	3.5%	5.0%	£900
Within-trial mortality	On	Off	£1011
Post-trial treatment effect	Off	On – 1 year	£255
Post-trial treatment effect	Off	On – 3 years	Dominant
Post-trial treatment effect	Off	On – 5 years	Dominant
Post-trial treatment effect – waning	Off	On – 5 years	Dominant
Overall treatment discontinuation	On	Off	£1414
Post-trial treatment discontinuation	On	Off	£1414
Time horizon	Lifetime	Trial follow-up	Dominant
Replacement therapy	By treatment arm	By overall trial	£1098
Perspective	Health service perspective	Societal perspective	£886

FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol; BUD: budesonide; FOR: formoterol; ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year.